Serveur d'exploration sur la grippe en Espagne

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Position document: IgE-mediated allergy to egg protein.

Identifieur interne : 000233 ( Main/Exploration ); précédent : 000232; suivant : 000234

Position document: IgE-mediated allergy to egg protein.

Auteurs : A. Martorell [Espagne] ; E. Alonso ; J. Boné ; L. Echeverría ; M C L Pez ; F. Martín ; S. Nevot ; A M Plaza

Source :

RBID : pubmed:23830306

Descripteurs français

English descriptors

Abstract

Egg is the food that most often causes allergy in young Spanish children, with an incidence of 2.4-2.6% in the first 2 years of life. The prevalence of sensitisation and allergy to egg is greater in children with allergy to cow's milk and in those suffering atopic dermatitis. The protein component from egg white is the cause of the allergic response in child. The major allergens in egg white are ovomucoid and ovalbumin. Most of the allergic reactions affect the skin, followed by gastrointestinal and respiratory systems. Egg allergy is one of the most common causes of severe anaphylaxis. The diagnosis of egg allergy is based on the existence of a suggestive clinical history, a positive allergy study and the subsequent application of controlled exposure testing, which represents the gold standard for confirming the diagnosis. The treatment of egg allergy is based on the avoidance of egg protein intake. A subgroup of egg-allergic patients are tolerant to cooked egg. In these cases, only uncooked egg must necessarily be avoided. Maintaining a diet with strict egg avoidance is difficult, and transgressions are relatively common. The patient, family, and school environment should receive education and training in the avoidance of egg and in the management of possible allergic reactions. With an avoidance diet, up to 15-20% of children will remain allergic and the severity of the reactions will increase over the years. In these more severe cases of egg-allergy, it becomes more difficult to adhere to the avoidance diet over the years, with a significant decrease in patient quality of life. Oral tolerance induction can be regarded as a therapeutic option for IgE-mediated egg allergy. The anti-IgE, omalizumab, might become another genuine therapeutic option for food allergy, not only to prevent allergic reactions after a contact with egg, but also as a complementary treatment to oral tolerance induction for egg allergy, with the purpose of reducing adverse reactions. The administration of influenza vaccine to children with egg allergy is safe in children that do not manifest severe reactions after egg intake, and in children who tolerate cooked egg. The triple viral vaccine (MMR) can be given to egg-allergic children in their usual vaccination centre, with no added risk. Different medicinal products can be formulated with egg proteins, and therefore should be avoided in children with egg allergy.

DOI: 10.1016/j.aller.2013.03.005
PubMed: 23830306


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Position document: IgE-mediated allergy to egg protein.</title>
<author>
<name sortKey="Martorell, A" sort="Martorell, A" uniqKey="Martorell A" first="A" last="Martorell">A. Martorell</name>
<affiliation wicri:level="1">
<nlm:affiliation>Allergy Department, H General Universitario, Valencia, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Allergy Department, H General Universitario, Valencia</wicri:regionArea>
<wicri:noRegion>Valencia</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Alonso, E" sort="Alonso, E" uniqKey="Alonso E" first="E" last="Alonso">E. Alonso</name>
</author>
<author>
<name sortKey="Bone, J" sort="Bone, J" uniqKey="Bone J" first="J" last="Boné">J. Boné</name>
</author>
<author>
<name sortKey="Echeverria, L" sort="Echeverria, L" uniqKey="Echeverria L" first="L" last="Echeverría">L. Echeverría</name>
</author>
<author>
<name sortKey="L Pez, M C" sort="L Pez, M C" uniqKey="L Pez M" first="M C" last="L Pez">M C L Pez</name>
</author>
<author>
<name sortKey="Martin, F" sort="Martin, F" uniqKey="Martin F" first="F" last="Martín">F. Martín</name>
</author>
<author>
<name sortKey="Nevot, S" sort="Nevot, S" uniqKey="Nevot S" first="S" last="Nevot">S. Nevot</name>
</author>
<author>
<name sortKey="Plaza, A M" sort="Plaza, A M" uniqKey="Plaza A" first="A M" last="Plaza">A M Plaza</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2013">2013 Sep-Oct</date>
<idno type="RBID">pubmed:23830306</idno>
<idno type="pmid">23830306</idno>
<idno type="doi">10.1016/j.aller.2013.03.005</idno>
<idno type="wicri:Area/Main/Corpus">00235</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">00235</idno>
<idno type="wicri:Area/Main/Curation">000235</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000235</idno>
<idno type="wicri:Area/Main/Exploration">000235</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Position document: IgE-mediated allergy to egg protein.</title>
<author>
<name sortKey="Martorell, A" sort="Martorell, A" uniqKey="Martorell A" first="A" last="Martorell">A. Martorell</name>
<affiliation wicri:level="1">
<nlm:affiliation>Allergy Department, H General Universitario, Valencia, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Allergy Department, H General Universitario, Valencia</wicri:regionArea>
<wicri:noRegion>Valencia</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Alonso, E" sort="Alonso, E" uniqKey="Alonso E" first="E" last="Alonso">E. Alonso</name>
</author>
<author>
<name sortKey="Bone, J" sort="Bone, J" uniqKey="Bone J" first="J" last="Boné">J. Boné</name>
</author>
<author>
<name sortKey="Echeverria, L" sort="Echeverria, L" uniqKey="Echeverria L" first="L" last="Echeverría">L. Echeverría</name>
</author>
<author>
<name sortKey="L Pez, M C" sort="L Pez, M C" uniqKey="L Pez M" first="M C" last="L Pez">M C L Pez</name>
</author>
<author>
<name sortKey="Martin, F" sort="Martin, F" uniqKey="Martin F" first="F" last="Martín">F. Martín</name>
</author>
<author>
<name sortKey="Nevot, S" sort="Nevot, S" uniqKey="Nevot S" first="S" last="Nevot">S. Nevot</name>
</author>
<author>
<name sortKey="Plaza, A M" sort="Plaza, A M" uniqKey="Plaza A" first="A M" last="Plaza">A M Plaza</name>
</author>
</analytic>
<series>
<title level="j">Allergologia et immunopathologia</title>
<idno type="eISSN">1578-1267</idno>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Allergens (immunology)</term>
<term>Animals (MeSH)</term>
<term>Antibodies, Anti-Idiotypic (therapeutic use)</term>
<term>Antibodies, Monoclonal, Humanized (therapeutic use)</term>
<term>Desensitization, Immunologic (methods)</term>
<term>Egg Hypersensitivity (diagnosis)</term>
<term>Egg Hypersensitivity (epidemiology)</term>
<term>Egg Hypersensitivity (therapy)</term>
<term>Egg Proteins (immunology)</term>
<term>Humans (MeSH)</term>
<term>Immunoglobulin E (immunology)</term>
<term>Immunoglobulin E (metabolism)</term>
<term>Incidence (MeSH)</term>
<term>Infant (MeSH)</term>
<term>Infant, Newborn (MeSH)</term>
<term>Omalizumab (MeSH)</term>
<term>Spain (MeSH)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr">
<term>Allergènes (immunologie)</term>
<term>Animaux (MeSH)</term>
<term>Anticorps anti-idiotypiques (usage thérapeutique)</term>
<term>Anticorps monoclonaux humanisés (usage thérapeutique)</term>
<term>Désensibilisation immunologique (méthodes)</term>
<term>Espagne (MeSH)</term>
<term>Humains (MeSH)</term>
<term>Hypersensibilité à l'oeuf (diagnostic)</term>
<term>Hypersensibilité à l'oeuf (thérapie)</term>
<term>Hypersensibilité à l'oeuf (épidémiologie)</term>
<term>Immunoglobuline E (immunologie)</term>
<term>Immunoglobuline E (métabolisme)</term>
<term>Incidence (MeSH)</term>
<term>Nourrisson (MeSH)</term>
<term>Nouveau-né (MeSH)</term>
<term>Omalizumab (MeSH)</term>
<term>Protéines d'oeuf (immunologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en">
<term>Allergens</term>
<term>Egg Proteins</term>
<term>Immunoglobulin E</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en">
<term>Immunoglobulin E</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en">
<term>Antibodies, Anti-Idiotypic</term>
<term>Antibodies, Monoclonal, Humanized</term>
</keywords>
<keywords scheme="MESH" type="geographic" xml:lang="en">
<term>Spain</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en">
<term>Egg Hypersensitivity</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr">
<term>Hypersensibilité à l'oeuf</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en">
<term>Egg Hypersensitivity</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr">
<term>Allergènes</term>
<term>Immunoglobuline E</term>
<term>Protéines d'oeuf</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en">
<term>Desensitization, Immunologic</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr">
<term>Immunoglobuline E</term>
</keywords>
<keywords scheme="MESH" qualifier="méthodes" xml:lang="fr">
<term>Désensibilisation immunologique</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en">
<term>Egg Hypersensitivity</term>
</keywords>
<keywords scheme="MESH" qualifier="thérapie" xml:lang="fr">
<term>Hypersensibilité à l'oeuf</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr">
<term>Anticorps anti-idiotypiques</term>
<term>Anticorps monoclonaux humanisés</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr">
<term>Hypersensibilité à l'oeuf</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Animals</term>
<term>Humans</term>
<term>Incidence</term>
<term>Infant</term>
<term>Infant, Newborn</term>
<term>Omalizumab</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr">
<term>Animaux</term>
<term>Espagne</term>
<term>Humains</term>
<term>Incidence</term>
<term>Nourrisson</term>
<term>Nouveau-né</term>
<term>Omalizumab</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr">
<term>Espagne</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Egg is the food that most often causes allergy in young Spanish children, with an incidence of 2.4-2.6% in the first 2 years of life. The prevalence of sensitisation and allergy to egg is greater in children with allergy to cow's milk and in those suffering atopic dermatitis. The protein component from egg white is the cause of the allergic response in child. The major allergens in egg white are ovomucoid and ovalbumin. Most of the allergic reactions affect the skin, followed by gastrointestinal and respiratory systems. Egg allergy is one of the most common causes of severe anaphylaxis. The diagnosis of egg allergy is based on the existence of a suggestive clinical history, a positive allergy study and the subsequent application of controlled exposure testing, which represents the gold standard for confirming the diagnosis. The treatment of egg allergy is based on the avoidance of egg protein intake. A subgroup of egg-allergic patients are tolerant to cooked egg. In these cases, only uncooked egg must necessarily be avoided. Maintaining a diet with strict egg avoidance is difficult, and transgressions are relatively common. The patient, family, and school environment should receive education and training in the avoidance of egg and in the management of possible allergic reactions. With an avoidance diet, up to 15-20% of children will remain allergic and the severity of the reactions will increase over the years. In these more severe cases of egg-allergy, it becomes more difficult to adhere to the avoidance diet over the years, with a significant decrease in patient quality of life. Oral tolerance induction can be regarded as a therapeutic option for IgE-mediated egg allergy. The anti-IgE, omalizumab, might become another genuine therapeutic option for food allergy, not only to prevent allergic reactions after a contact with egg, but also as a complementary treatment to oral tolerance induction for egg allergy, with the purpose of reducing adverse reactions. The administration of influenza vaccine to children with egg allergy is safe in children that do not manifest severe reactions after egg intake, and in children who tolerate cooked egg. The triple viral vaccine (MMR) can be given to egg-allergic children in their usual vaccination centre, with no added risk. Different medicinal products can be formulated with egg proteins, and therefore should be avoided in children with egg allergy. </div>
</front>
</TEI>
<pubmed>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">23830306</PMID>
<DateCompleted>
<Year>2014</Year>
<Month>07</Month>
<Day>14</Day>
</DateCompleted>
<DateRevised>
<Year>2015</Year>
<Month>11</Month>
<Day>19</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1578-1267</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>41</Volume>
<Issue>5</Issue>
<PubDate>
<MedlineDate>2013 Sep-Oct</MedlineDate>
</PubDate>
</JournalIssue>
<Title>Allergologia et immunopathologia</Title>
<ISOAbbreviation>Allergol Immunopathol (Madr)</ISOAbbreviation>
</Journal>
<ArticleTitle>Position document: IgE-mediated allergy to egg protein.</ArticleTitle>
<Pagination>
<MedlinePgn>320-36</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.aller.2013.03.005</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0301-0546(13)00140-7</ELocationID>
<Abstract>
<AbstractText>Egg is the food that most often causes allergy in young Spanish children, with an incidence of 2.4-2.6% in the first 2 years of life. The prevalence of sensitisation and allergy to egg is greater in children with allergy to cow's milk and in those suffering atopic dermatitis. The protein component from egg white is the cause of the allergic response in child. The major allergens in egg white are ovomucoid and ovalbumin. Most of the allergic reactions affect the skin, followed by gastrointestinal and respiratory systems. Egg allergy is one of the most common causes of severe anaphylaxis. The diagnosis of egg allergy is based on the existence of a suggestive clinical history, a positive allergy study and the subsequent application of controlled exposure testing, which represents the gold standard for confirming the diagnosis. The treatment of egg allergy is based on the avoidance of egg protein intake. A subgroup of egg-allergic patients are tolerant to cooked egg. In these cases, only uncooked egg must necessarily be avoided. Maintaining a diet with strict egg avoidance is difficult, and transgressions are relatively common. The patient, family, and school environment should receive education and training in the avoidance of egg and in the management of possible allergic reactions. With an avoidance diet, up to 15-20% of children will remain allergic and the severity of the reactions will increase over the years. In these more severe cases of egg-allergy, it becomes more difficult to adhere to the avoidance diet over the years, with a significant decrease in patient quality of life. Oral tolerance induction can be regarded as a therapeutic option for IgE-mediated egg allergy. The anti-IgE, omalizumab, might become another genuine therapeutic option for food allergy, not only to prevent allergic reactions after a contact with egg, but also as a complementary treatment to oral tolerance induction for egg allergy, with the purpose of reducing adverse reactions. The administration of influenza vaccine to children with egg allergy is safe in children that do not manifest severe reactions after egg intake, and in children who tolerate cooked egg. The triple viral vaccine (MMR) can be given to egg-allergic children in their usual vaccination centre, with no added risk. Different medicinal products can be formulated with egg proteins, and therefore should be avoided in children with egg allergy. </AbstractText>
<CopyrightInformation>Copyright © 2013 SEICAP. Published by Elsevier Espana. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Martorell</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Allergy Department, H General Universitario, Valencia, Spain.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Alonso</LastName>
<ForeName>E</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Boné</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Echeverría</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>López</LastName>
<ForeName>M C</ForeName>
<Initials>MC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Martín</LastName>
<ForeName>F</ForeName>
<Initials>F</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Nevot</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Plaza</LastName>
<ForeName>A M</ForeName>
<Initials>AM</Initials>
</Author>
<Author ValidYN="Y">
<CollectiveName>Food Allergy Committee of SEICAP</CollectiveName>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>07</Month>
<Day>02</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Spain</Country>
<MedlineTA>Allergol Immunopathol (Madr)</MedlineTA>
<NlmUniqueID>0370073</NlmUniqueID>
<ISSNLinking>0301-0546</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000485">Allergens</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000888">Antibodies, Anti-Idiotypic</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004527">Egg Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>2P471X1Z11</RegistryNumber>
<NameOfSubstance UI="D000069444">Omalizumab</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>37341-29-0</RegistryNumber>
<NameOfSubstance UI="D007073">Immunoglobulin E</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName UI="D000485" MajorTopicYN="N">Allergens</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000888" MajorTopicYN="N">Antibodies, Anti-Idiotypic</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D003888" MajorTopicYN="N">Desensitization, Immunologic</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D021181" MajorTopicYN="N">Egg Hypersensitivity</DescriptorName>
<QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D004527" MajorTopicYN="N">Egg Proteins</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D007073" MajorTopicYN="N">Immunoglobulin E</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000069444" MajorTopicYN="N">Omalizumab</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D013030" MajorTopicYN="N" Type="Geographic">Spain</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Children</Keyword>
<Keyword MajorTopicYN="N">Diagnosis</Keyword>
<Keyword MajorTopicYN="N">Egg allergy</Keyword>
<Keyword MajorTopicYN="N">Food allergy</Keyword>
<Keyword MajorTopicYN="N">Oral immunotherapy</Keyword>
<Keyword MajorTopicYN="N">Outcomes</Keyword>
<Keyword MajorTopicYN="N">Tolerance</Keyword>
<Keyword MajorTopicYN="N">Treatment</Keyword>
<Keyword MajorTopicYN="N">Vaccines</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="received">
<Year>2013</Year>
<Month>03</Month>
<Day>16</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted">
<Year>2013</Year>
<Month>03</Month>
<Day>25</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2013</Year>
<Month>7</Month>
<Day>9</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2013</Year>
<Month>7</Month>
<Day>9</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2014</Year>
<Month>7</Month>
<Day>16</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">23830306</ArticleId>
<ArticleId IdType="pii">S0301-0546(13)00140-7</ArticleId>
<ArticleId IdType="doi">10.1016/j.aller.2013.03.005</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations>
<list>
<country>
<li>Espagne</li>
</country>
</list>
<tree>
<noCountry>
<name sortKey="Alonso, E" sort="Alonso, E" uniqKey="Alonso E" first="E" last="Alonso">E. Alonso</name>
<name sortKey="Bone, J" sort="Bone, J" uniqKey="Bone J" first="J" last="Boné">J. Boné</name>
<name sortKey="Echeverria, L" sort="Echeverria, L" uniqKey="Echeverria L" first="L" last="Echeverría">L. Echeverría</name>
<name sortKey="L Pez, M C" sort="L Pez, M C" uniqKey="L Pez M" first="M C" last="L Pez">M C L Pez</name>
<name sortKey="Martin, F" sort="Martin, F" uniqKey="Martin F" first="F" last="Martín">F. Martín</name>
<name sortKey="Nevot, S" sort="Nevot, S" uniqKey="Nevot S" first="S" last="Nevot">S. Nevot</name>
<name sortKey="Plaza, A M" sort="Plaza, A M" uniqKey="Plaza A" first="A M" last="Plaza">A M Plaza</name>
</noCountry>
<country name="Espagne">
<noRegion>
<name sortKey="Martorell, A" sort="Martorell, A" uniqKey="Martorell A" first="A" last="Martorell">A. Martorell</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippeEspagneV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000233 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000233 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    GrippeEspagneV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:23830306
   |texte=   Position document: IgE-mediated allergy to egg protein.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:23830306" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a GrippeEspagneV1 

Wicri

This area was generated with Dilib version V0.6.37.
Data generation: Fri Sep 25 11:01:38 2020. Site generation: Sat Feb 13 17:38:04 2021